US FDA’s Post-Aduhelm Reforms Include Updated Alzheimer’s Development Guidance, Record-Keeping On Sponsor Meetings

 
• By Nielsen Hobbs
  
Alzheimer's seas perspectives
FDA will continue to have to navigate the treacherous seas of the Aduhelm controversy in 2023. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Agency Leadership

More from Pink Sheet